- Home
- HPP vs PCRX Comparison
HPP vs PCRX Comparison
Compare HPP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- PCRX
- Stock Information
- Founded
- HPP 2009
- PCRX 2006
- Country
- HPP United States
- PCRX United States
- Employees
- HPP N/A
- PCRX N/A
- Industry
- HPP Real Estate
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- HPP Finance
- PCRX Health Care
- Exchange
- HPP Nasdaq
- PCRX Nasdaq
- Market Cap
- HPP 660.6M
- PCRX 604.7M
- IPO Year
- HPP 2010
- PCRX 2011
- Fundamental
- Price
- HPP $3.06
- PCRX $17.38
- Analyst Decision
- HPP Hold
- PCRX Buy
- Analyst Count
- HPP 11
- PCRX 10
- Target Price
- HPP $5.95
- PCRX $26.60
- AVG Volume (30 Days)
- HPP 2.7M
- PCRX 547.0K
- Earning Date
- HPP 11-12-2024
- PCRX 11-06-2024
- Dividend Yield
- HPP 6.53%
- PCRX N/A
- EPS Growth
- HPP N/A
- PCRX N/A
- EPS
- HPP N/A
- PCRX N/A
- Revenue
- HPP $847,713,000.00
- PCRX $694,957,000.00
- Revenue This Year
- HPP N/A
- PCRX $4.59
- Revenue Next Year
- HPP $2.73
- PCRX N/A
- P/E Ratio
- HPP N/A
- PCRX N/A
- Revenue Growth
- HPP N/A
- PCRX 4.40
- 52 Week Low
- HPP $3.05
- PCRX $11.16
- 52 Week High
- HPP $9.86
- PCRX $35.95
- Technical
- Relative Strength Index (RSI)
- HPP 24.07
- PCRX 58.45
- Support Level
- HPP $4.04
- PCRX $16.00
- Resistance Level
- HPP $4.51
- PCRX $18.34
- Average True Range (ATR)
- HPP 0.26
- PCRX 0.84
- MACD
- HPP -0.12
- PCRX -0.05
- Stochastic Oscillator
- HPP 0.92
- PCRX 58.97
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.